Upadacitinib + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Segmental Vitiligo
Conditions
Non-Segmental Vitiligo
Trial Timeline
Jun 30, 2021 → Aug 29, 2023
NCT ID
NCT04927975About Upadacitinib + Placebo
Upadacitinib + Placebo is a phase 2 stage product being developed by AbbVie for Non-Segmental Vitiligo. The current trial status is completed. This product is registered under clinical trial identifier NCT04927975. Target conditions include Non-Segmental Vitiligo.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06118411 | Phase 3 | Active |
| NCT06012240 | Phase 3 | Recruiting |
| NCT05843643 | Phase 3 | Recruiting |
| NCT05889182 | Phase 3 | Recruiting |
| NCT04927975 | Phase 2 | Completed |
| NCT04430855 | Phase 2 | Completed |
| NCT04169373 | Phase 3 | Completed |
| NCT02955212 | Phase 3 | Completed |
| NCT03178487 | Phase 2 | Completed |
| NCT02925117 | Phase 2 | Completed |
Competing Products
8 competing products in Non-Segmental Vitiligo
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR0302 Tablets + SHR0302 Base Gel + SHR0302 Placebo Tablets + SHR0302 Base Placebo Gel | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| MK-6194 + Placebo | Merck | Phase 2 | 52 |
| GIA632 + Placebo | Novartis | Phase 2 | 52 |
| PF-06651600 + PF-06651600 + PF-06651600 + PF-06651600 + PF-06651600 + placebo + PF06700841 | Pfizer | Phase 2 | 51 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 3 | 74 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 3 | 74 |
| Roflumilast topical 0.3% foam | Arcutis Biotherapeutics | Phase 2 | 47 |
| VYN201 Gel + Vehicle Gel | Vyne Therapeutics | Phase 2 | 44 |